Clinical Trials | December 24, 2025
Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial
Adverse events were consistent with valbenazine’s established safety profile
Adverse events were consistent with valbenazine’s established safety profile
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The combination also outperformed chemotherapy on another important secondary endpoint
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Subscribe To Our Newsletter & Stay Updated
